-
Oxford-AstraZeneca promised its COVID-19 vaccine would be effective, cheap and available worldwide. Five months after its launch, the path forward has been anything but smooth.
-
The administration has faced growing calls to send its stockpile of the AstraZeneca vaccine, which is not yet cleared for use in the U.S., to help countries hit hard by the virus.
-
"Its benefits continue to be far greater than its risks," said Dr. Sabine Straus of the agency's risk committee. It found no increase in the overall risk of blood clots with the vaccine.
-
A small study in South Africa has raised concerns about the effectiveness of the AstraZeneca vaccine, particularly in fighting virus variants.
-
A study raised concerns about its effectiveness against the coronavirus variant sweeping through the country — although the data is too preliminary for definitive conclusions.
-
European Commission President Ursula von der Leyen announced Sunday that AstraZeneca would also deliver the vaccines one week earlier than originally scheduled.
-
"I expect the company to deliver the 400 million doses as agreed," said European Commission President Ursula von der Leyen.
-
"The companies must deliver. They must honor their obligations," the European Commission's president said after both AstraZeneca and Pfizer said they were experiencing shipping issues.
-
The pharmaceutical company made the announcement on Monday, saying that one dosing regimen showed the vaccine was 90% effective in preventing infection.